The Bone Cancer Research Trust funds research from a range of disciplines to help to find the cause or cure of primary bone cancer. We also fund research that will improve the care for patients with this disease. You can download our full strategy here.

Our Grant Programme:

Find full details of the Bone Cancer Research Trust's 'Grant Types', their funding value and the applications accepted for these grants by clicking here.

Only about half of all the applications we receive will be funded.

If you require any further information or have any queries regarding our grant programme or the grant types we fund, please contact a member of our research team at research@bcrt.org.uk

The Bone Cancer Research Trust is proud to be a member of the Association of Medical Research Charities (AMRC), the national membership organisation of leading medical and health research charities

AMRC membership is the hallmark of quality research funding. To be accepted into the AMRC membership, charities must demonstrate that they follow the AMRC's rigorous standards in peer review, and therefore, providing supporters with reassurance that their money is being spent on only the highest quality research.

Membership also helps our research money go further:

• Funding from AMRC members that is awarded via open competition is eligible for the Charity Research Support Fund (CRSF). This means that for every pound BCRT fund another 20p is invested in universities. This means that BCRT funding can be spent purely on research and the CRSF can allow the maintenance of labs, lighting and heating – the full economic costs of conducting research.
• The AcoRD agreement ensures that AMRC members only pay the direct research costs of clinical research in the NHS. The Department of Health will meet all costs for local trial co-ordination and management, data collection, and regulatory fees.

By working with member charities and partners, the AMRC aims to support the sector’s effectiveness and advance medical research by developing best practice, providing information and guidance, improving public dialogue about research and science, and influencing government policy.

As a member of the AMRC, we support their statement on the use of animals in research and their statement on supporting research in universities.

The role of our Independent Scientific Advisory Panel is to evaluate all grant applications, and recommend to the Board of Trustees the grants that are suitable for funding.

The panel is comprised of experts who review all our grant applications for relevance, scientific merit, cost and suitability of the applicant. They also conduct interviews for Studentship and Fellowship applications.

• Chair: Professor Pamela Kearns, University of Birmingham
• Lay member: Mr Simon Allocca
• Member: Professor Andy Hall, Newcastle University
• Member: Professor Robert Brown, Institute of Cancer Research and Imperial College London
• Member: Dr Richard Grose, Barts Cancer Institute
• Member:Dr Deborah Stocken, Newcastle University

To view our full 2017-2022 grant programme in line with our 5 year strategy, please view the full strategy document here.

CCLG Tissue Bank Pilot Grants

Our friends at CCLG currently have funding available for pilot grants looking at a variety of childhood cancers, including Ewing Sarcoma.

CCLG Tissue Bank Pilot Grants - 2018

This year marks a significant milestone for the CCLG Tissue Bank, celebrating 20 years of supporting childhood cancer research. To commemorate this achievement CCLG are inviting researchers to apply for funding for novel and innovative biological research projects into a range of childhood cancers.

The aim of these pilot studies should be to investigate the new biology of cancers, potential predictive and prognostic biomarkers to improve diagnosis or treatment, or to validate research methods/ tools for further extensive studies.

These pilot grants enable UK or Ireland based researchers to access samples from the CCLG Tissue Bank in order to test new hypotheses to obtain preliminary data, for extensive biological studies which are then supported by larger project/programme grants from other funding bodies.

Funding is available into a variety of childhood cancers. These are:

• Ewing’s sarcoma
• Langerhans cell histiocytosis (LCH)
• Low grade gliomas (e.g. grade I/ II astrocytoma, meningioma and oligodendroglioma subtypes)
• Medulloblastoma
• Non-Hodgkin lymphoma (T-Cell variant only)
• Rare tumours (e.g. adenoma, carcinoma and sarcoma subtypes; retinoblastoma (germline DNA samples only))
• Rhabdoid tumours
• Wilms tumour

For further information and how to apply please see: http://www.cclg.org.uk/tissue-bank-pilot-grants

Researcher Database

If you would like to be added to our 'Researcher Database' in order to be the first to hear of our future grant openings, conferences of interest or to find out more information on our research, please contact our research team at research@bcrt.org.uk.

If you would like to be added to our 'Researcher Database' in order to be the first to hear of our future grant openings, conferences of interest or to find out more information on our research, please contact our research team at research@bcrt.org.uk.

Funding Remit

The Bone Cancer Research Trust are dedicated to improving the outcomes for patients with primary bone cancer. One of the main ways in which we aim to do this, is by funding cutting edge research. Our funding is dedicated to projects that are genuinely centered around improving knowledge of this disease, with a clear line of sight to patient benefit and with good prospects of being published in high impact journals.

We fund research into the causes of the disease, research looking at cures and treatments and also research looking at care and quality of life; funding basic ideas through to translational research projects. Please download our full Research Funding Remit here to learn more (Updated February 2017).

Resubmission Policy

At the Bone Cancer Research Trust, we do not allow the resubmission of any previously unsuccessful proposals, unless you have been explicitly invited to resubmit.

Details of any requirements for resubmission, as requested by our Independent Scientific Advisory Panel, will be described in detail in the application and review feedback. You can download our resubmissions policy here (updated January 2017).